Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp. RVXCF


Primary Symbol: T.RVX Alternate Symbol(s):  T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix Announces Appointment of New Chief Scientific Officer

GlobeNewswire 3 days ago

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

GlobeNewswire June 21, 2022

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

GlobeNewswire June 8, 2022

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

GlobeNewswire May 9, 2022

Resverlogix Announces One-Year Extension of Debenture

GlobeNewswire April 19, 2022

Resverlogix's (TSX:RVX) apabetalone featured in the American Journal of Respiratory and Critical Care Medicine

Brieanna McCutcheon  March 17, 2022

Apabetalone's Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

GlobeNewswire March 17, 2022

Resverlogix (TSX:RVX)steps up Phase 2b study for COVID-19 treatment

Akanksha Kumar February 17, 2022

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

GlobeNewswire February 17, 2022

InvestmentPitch Media Video Discusses Resverlogix' Enrollment and Dosing of Patients in a Phase 2b Clinical Trial at a Site at the University of Alberta Hospital in Edmonton, to evaluate Apabetalone as a Potential Oral Treatment for COVID-19 - Video Available on Investmentpitch.com

Newsfile January 19, 2022

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

GlobeNewswire January 18, 2022

Resverlogix: The Future of Drug Development, CEO Clip Video

Newsfile December 16, 2021

Resverlogix Announces Corporate Update Webcast and Conference Call

GlobeNewswire December 13, 2021

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

GlobeNewswire November 3, 2021

InvestmentPitch Media Video Discusses Resverlogix' Active Discussions with the Kingdom of Morocco's Ministry of Health for the Launch of COVID-19 Clinical Studies Involving Apabetalone - Video Available on Investmentpitch.com

Newsfile November 2, 2021

Resverlogix (TSX:RVX) in discussions for COVID-19 clinical studies in Morocco

Trevor Abes  November 1, 2021

Resverlogix In Active Discussions With The Kingdom of Morocco's Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

GlobeNewswire November 1, 2021

Resverlogix to Participate in Leading Scientific Conferences

GlobeNewswire October 29, 2021

Resverlogix to Present at Upcoming Conferences

GlobeNewswire October 13, 2021

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

GlobeNewswire October 12, 2021